Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be useful for the treatment of subacute sclerosing panencephalitis, progressive supranuclear palsy, frontotemporal dementia and Alzheimer's disease, among others.

Shanghai Litedd Co. Ltd. has divulged 8-oxo-3-azabicyclo[3.2.1]octane compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.

Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.

Medshine Discovery Inc. has synthesized macrocyclic compounds acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infections.

Louisiana State University has disclosed 5-HT2 receptor ligands reported to be useful for the treatment of anxiety, depression, asthma, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, rheumatoid arthritis, chronic pain and post-stress traumatic disorder, among others.

Zoetis Services LLC has described 5-HT2B receptor antagonists reported to be useful for the treatment of heart failure.

Carna Biosciences Inc. and Sumitomo Pharma Co. Ltd. have identified dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) inhibitors reported to be useful for the treatment of cancer, depression, epilepsy, dementia, psychosis, thyroid and gastrointestinal disorders, among others.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.

Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.